Skip to main content

Table 1 Baseline characteristics of patients in the treatment and control groups

From: Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial

Characteristics

Indomethacin group

(N = 82)

Glycerin group

(N = 84)

P

Female

Male

51 (62.19 %)

31 (37.80 %)

59 (70.23 %)

25 (29.76 %)

0.273

Age (years)

51.59 ± 18.55

54.0 ± 17.85

0.394

Outpatients

46

45

0.74

Hospitalized

36

39

Without comorbidity

56

54

0.427

Comorbid conditions

26

30

 Diabetes Mellitus type 2

12

14

 Hypertension

7

7

 Dyslipidemia

2

2

 Hypothyroidism

1

0

 COPD

1

1

 Hepatic cirrhosisa

1

2

 Ischemic heart disease

1

1

 HIV

0

1

 Asthma

1

2

Normal total bilirubin pre-ERCP

26

24

0.660

Elevated total bilirubin pre-ERCP

56

60

Previous cholecystectomy

42

40

0.643

Dilated bile duct by imaging studies pre-ERCP

56

62

0.506

Post-ERCP diagnostics

  

0.35

 Choledocolithiasis

34

32

 Begin biliary stenosis and/or leakage

18

14

 Suspected sphincter of Oddi dysfunction

12

15

 Normal cholangiogram and/or pancreatogram

8

11

 Malignant biliary tract stenosis

8

9

 Pancreatic fistula

2

3

Pre-ERCP amylase level (U/L)

57.39 ± 21.56

55.36 ± 20.77

0.540

  1. aEtiology in the indomethacin group: chronic hepatitis due to hepatitis C virus in 1 patient. Glycerin group etiologies in chronic hepatitis due to hepatitis C virus in 1 patient and primary biliary cirrhosis in 1 patient.